LONDON, December 8, 2015 /PRNewswire/ --
Ovarian cancer treatment has a strong pipeline of 462 diverse and innovative products in active development, says GBI Research.
Analysis from business intelligence provider GBI Research - Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation - states that as the ovarian cancer therapeutics market becomes more diverse, it will become less reliant on indiscriminate and highly cytotoxic chemotherapy regimens.
The range of new products in active development signals significant potential for alternatives to chemotherapy, which does not target specific proteins in aberrant pathways in ovarian cancer. For a complimentary sample of this research, please visit the GBI Research website.
Analyst for GBI Research Joshua Libberton: "Despite limited therapeutic options for ovarian cancer patients at the moment, almost 52% of ovarian cancer products in active development in the pipeline are considered to be first-in-class, as they have a molecular target not associated with any marketed products.
"As the current ovarian cancer market has a large generic presence, and relatively few novel active pharmaceutical ingredients, the market has stagnated, leaving a large portion of the ovarian cancer population with significant unmet needs.
"Currently, ovarian cancer has the highest mortality rate of all gynaecological cancers and is fatal in a majority of patients, rendering it imperative that more effective therapies are developed."
According to GBI Research, the high proportion of first-in-class innovation implies that the industry is pursuing novel approaches to treatment and reducing the focus on established therapies. Although innovation to date has been slow, greater disease understanding and awareness has created an environment in which it will thrive.
Libberton continues: "In addition to the use of existing platinum-based chemotherapy, treatments such as anti-angiogenic treatments and Poly ADP Ribose Polymerase inhibitors are expected to have a positive impact on ovarian cancer survival in particular patient subsets.
"The pipeline is showing clear signs of innovation in ovarian cancer treatment, with many products deviating away from standard chemotherapy targets and a high proportion of first-in-class drugs.
"Despite fewer innovative products reaching the ovarian cancer market than other indications in the past, there is hope that an industry-wide perception of high rewards for successful first-in-class products and an innovative ovarian cancer pipeline can provide improved treatment options."
About GBI Research
GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.
For more information, please contact GBI Research on: +44 161 359 5817
For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.
Follow GBI Research online for the latest healthcare industry updates:
SOURCE GBI Research